Experienced in Bone Tumor

Dr. Stephen S. Grubbs

Oncology
4701 Ogletown Stanton Rd, Suite 2200, 
Newark, DE 
Experienced in Bone Tumor
4701 Ogletown Stanton Rd, Suite 2200, 
Newark, DE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Grubbs is an Oncologist in Newark, Delaware. Dr. Grubbs is rated as an Experienced provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Breast Cancer, and Bone Tumor.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Bone Tumor.

Specialties
Oncology
Licenses
Internal Medicine in DE
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareFirst
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO

Locations

4701 Ogletown Stanton Rd, Suite 2200, Newark, DE 19713

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 4 Less Clinical Trials

21 Total Publications

Sustaining Improvements in Colorectal Cancer Across Delaware:: A Look at Racial Disparities a Decade Later.
Sustaining Improvements in Colorectal Cancer Across Delaware:: A Look at Racial Disparities a Decade Later.
Journal: Delaware journal of public health
Published: August 30, 2024
Similar Doctors
Distinguished in Bone Tumor
Dr. Christian F. Meyer
Oncology
Distinguished in Bone Tumor
Dr. Christian F. Meyer
Oncology

Johns Hopkins University

601 N Caroline St, 
Baltimore, MD 
 (56.0 miles away)
410-955-5080
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christian Meyer is an Oncologist in Baltimore, Maryland. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Bone Tumor. Dr. Meyer is currently accepting new patients.

Distinguished in Bone Tumor
Dr. Margaret Von-Mehren
Oncology | Transplant Surgery
Distinguished in Bone Tumor
Dr. Margaret Von-Mehren
Oncology | Transplant Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (35.4 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Margaret Von-Mehren is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Von-Mehren is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. Her top areas of expertise are Gastrointestinal Stromal Tumor, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Retroperitoneal Liposarcoma.

Distinguished in Bone Tumor
Dr. Atrayee Basu-Mallick
Hematology Oncology | Oncology
Distinguished in Bone Tumor
Dr. Atrayee Basu-Mallick
Hematology Oncology | Oncology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (32.9 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Atrayee Basu-Mallick is a Hematologist Oncology specialist and an Oncologist in Philadelphia, Pennsylvania. Dr. Basu-Mallick is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. Her top areas of expertise are Bone Tumor, Colorectal Cancer, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Pancreaticoduodenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grubbs's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile